The difference between effectiveness and efficacy of antimalarial drugs in Kenya
View/ Open
Date
2004Author
Amin, AA
Hughes, DA
Marsh, V
Abuya, TO
Kokwaro, G
Winstanley, PA
Ochola, SA
Snow, RW
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Objective:To demonstrate the difference between effectiveness and efficacy of antimalarial (AM) drugs in Kenya.
Methods:We undertook a series of linked surveys in four districts of Kenya between 2001 and 2002 on (i) community usage of nationally recommended first- and second-line AM drugs; (ii) commonly stocked AM products in the retail and wholesale sectors; and (iii) quality of the most commonly available first- and second-line AM products. These were combined with estimates of adherence and clinical efficacy to derive overall drug effectiveness. Results: The overall modelled effectiveness for sulphadoxine-pyrimethamine (SP) was estimated to be 62% compared with 85% for reported SP clinical efficacy. For amodiaquine the modelled effectiveness was 48% compared with 99% reported efficacy during the same time period. Conclusion: The quality of AM products and patient adherence to dosage regimens are important determinants of drug effectiveness, and should be measured alongside clinical efficacy. Post-registration measures to regulate drug quality and improve patient adherence would contribute significantly to AM drug performance
URI
http://www.ncbi.nlm.nih.gov/pubmed/15361109http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/31044
Citation
Trop Med Int Health. 2004 Sep;9(9):967-74Publisher
University of Nairobi College of Humanities Sciences
Collections
- Faculty of Health Sciences (FHS) [10377]